Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Go back to Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia| (NASDAQ: ALLO) | Delayed: 2.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.10 | 52 Week High | $ | |||
| Open | $2.03 | 52 Week Low | $ | |||
| Day High | $2.17 | P/E | N/A | |||
| Day Low | $2.03 | EPS | $ | |||
| Volume | 2,436,422 | |||||
